Oncology

The widely publicized untested oncology drug scandal could lead to better clinical practice.

Catalent Pharma Solutions and Moderna Therapeutics supports manufacturing of cancer vaccines.

Tennessee pharmacist admits to falsifying prior authorizations, medical lab reports, and drug test results for at least 51 hepatitis C patients prescribed Sovaldi, Harvoni, Viekira Pak, and Daklinza.

Pharmacists should keep tabs on the mental state of patients treated for lung cancer.

First-line pembrolizumab in addition to standard chemotherapy improved response rates and survival in patients with advanced non-small cell lung cancer.

Androgen deprivation therapy may increase the risk of developing dementia.

High-risk soft tissue sarcoma patients given anthracycline plus ifosfamide were found to have significant increases in survival.

Top news of the day from across the health care landscape.

Superior progression-free survival achieved with cabozantinib over sunitinib in patients with metastatic renal cell carcinoma.

Supplements given to prostate cancer patients following radiotherapy could harm disease outcomes.

Study challenges previous findings that suggest night shift work increases the risk of breast cancer.

Immunotherapy showed promise in first- and second-line therapy for patients with metastatic bladder cancer.

Survey findings show a high level of integration of palliative care in advanced cancer patients.

Top news of the day from across the health care landscape.

Xtandi’s revised label will include results a study showing improve progression-free survival in prostate cancer.

Experimental treatment uses mRNA expression from tumors to identify responders.

No change in prostate-specific antigen tests for cancer was found before and after new screening guidelines.

Top news of the day from across the health care landscape.

Researchers examine interventions that may improve adherence in chronic viral hepatitis care.

Hookah bars are on the rise around the world despite their being associated with many health risks.

Top articles of the week from The American Journal of Pharmacy Benefits.

Top news of the week in oncology and cancer drug development.

New data indicates men of African American and Hispanic descent are less likely to undergo therapy for prostate cancer compared with Caucasian men.

Targeting the uracil-DNA glycosylase enzyme may help treat certain types of non-Hodgkin’s lymphoma.

Top news of the day from across the health care landscape.

Efficacy and safety data shows encouraging results for rucaparib in BRCA-mutation ovarian cancer.

Obstacles exist in making testing and treatment for hepatitis C routine practice in prison.

In case you missed it, here's the hottest news in pharmacy this week: